Pharmacokinetic considerations in phenytoin pharmacotherapy: preventing overdoses and underdoses
Profeta, L.M.; Bradbury, K.; Mehl, B.
Mount Sinai Journal of Medicine new York 62(4): 312-314
1995
ISSN/ISBN: 0027-2507 PMID: 7565857 Document Number: 454669
Document emailed within 1 workday
Related Documents
Stüttgen, G.; Täuber, U.; Bauer, E.; Zesch, A. 1986: Local and transcutaneous pharmacotherapy. Pharmacokinetic principles and clinical evaluation Der Hautarzt; Zeitschrift für Dermatologie Venerologie und verwandte Gebiete 37(2): 65-76Rui, J.Z.; Cai, M.H.; Chu, X.M.; Chen, G. 1995: NONMEM approach for estimating population pharmacokinetic parameters of phenytoin in Chinese epileptics Yao Xue Xue Bao 30(3): 172-178
Risby, E.D. 1996: Ethnic considerations in the pharmacotherapy of mood disorders Psychopharmacology Bulletin 32(2): 231-234
Browne, T.R.; Szabo, G.K.; Davoudi, H.; Josephs, E.G. 1994: Determination of pharmacokinetic drug interactions with carbamazepine and phenytoin using stable isotope labeling and simple high-performance liquid chromatography/ultraviolet detection technique Neurology 44(12): 2410-2411
Dworacka, M.; Nowocień, T. 2017: Undesirable pharmacokinetic drug-to-drug interactions affecting the effectiveness and safety of anti-infectious pharmacotherapy Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 42(248): 61-64
Ereshefsky, L. 1999: Pharmacologic and pharmacokinetic considerations in choosing an antipsychotic Journal of Clinical Psychiatry 60(Suppl 10): 20-30
Mazière, B.; Delforge, J. 1997: Pharmacokinetic considerations in the PET and SPECT evaluation of CNS receptors Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine and the International Association of Radiopharmacology 41(2): 119-126
Westlake, W.J. 1974: Statistical considerations in the planning and analysis of pharmacokinetic experiments Acta Pharmaceutica Suecica 11(6): 632
D'Incalci, M.; Schüller, J.; Colombo, T.; Zucchetti, M.; Riva, A. 1998: Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations Seminars in Oncology 25(6 Suppl 13: 16-20
Kahan, B.D. 1996: Pharmacokinetic considerations in the therapeutic application of cyclosporine in renal transplantation Transplantation Proceedings 28(4): 2143-2146
LeWitt, P.A. 1992: Clinical studies with and pharmacokinetic considerations of sustained-release levodopa Neurology 42(1 Suppl 1: 29-32; Discussion: 57-60
Parashos, P.J.; Dugan, W.M.; Fry, M.W. 1987: Continuous infusion metoclopramide: clinical trials, pharmacokinetic considerations and cost-effectiveness Progress in Clinical and Biological Research 248: 303-311
Jefferys, R.J. 2005: Lower phenytoin serum levels in persons switched from brand to generic phenytoin Neurology 65(4): 657-8; Author Reply 657-8
Wierzchowiecki, M.; Swiderczuk, A.; Dyderski, S.; Masiakowski, J.; Jazienicki, B. 1987: Studies of the biological availability of phenytoin preparations (Polfa) and micronized phenytoin in patients with cardiac rhythm disorders Kardiologia Polska 30(9): 577-582
Overduin, L.M. 1992: Clinical trial on sustained-release phenytoin. Preliminary results of the open, non-controlled study. the Phenytoin Trial Group on Canine Epilepsy Tijdschrift Voor Diergeneeskunde 117(Suppl 1): 27s-28s
Henry, A.F. 1983: Overdoses of entrophen Canadian Medical Association Journal 128(10): 1142
Bryant, S.M.; Zilberstein, J.; Cumpston, K.L.; Magdziarz, D.D.; Costerisan, D.D. 2003: A case series of ziprasidone overdoses Veterinary and Human Toxicology 45(2): 81-82
Pimentel, L.; Trommer, L. 1994: Cyclic antidepressant overdoses. a review Emergency Medicine Clinics of North America 12(2): 533-547
Godfrey, B.D.; George, T.K.; Bodiwala, G.G. 1984: Overdoses and ingestions: one hospital's experience Practitioner 228(1394): 755-757
Kalter, H.D.; Ruttenber, A.J.; Zack, M.M. 1989: Temporal clustering of heroin overdoses in Washington, DC Journal of Forensic Sciences 34(1): 156-163